资金流向方面，主力资金净流入146.07万元，特大单买入0.00元，占比0.00%，卖出104.81万元，占比 1.78%；大单买入1234.20万元，占比20.98%，卖出983.32万元，占比16.72%。 10月10日，金石亚药盘中上涨2.00%，截至14:27，报9.68元/股，成交5882.58万元，换手率1.79%，总市 值38.89亿元。 金石亚药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：医药电商、抗流感、中 药、零售药店、生物医药等。 截至6月30日，金石亚药股东户数2.28万，较上期增加14.00%；人均流通股15010股，较上期减少 12.28%。2025年1月-6月，金石亚药实现营业收入4.92亿元，同比减少5.80%；归母净利润6574.54万元， 同比增长67.71%。 分红方面，金石亚药A股上市后累计派现1.70亿元。近三年，累计派现7191.22万元。 责任编辑：小浪快报 金石亚药今年以来股价涨18.32%，近5个交易日涨0.73%，近20日跌3.49%，近60日跌3.39%。 今年以来金石亚药已经1次登上龙虎榜，最近一次登上龙虎榜为1月6日，当日龙虎榜净买 ...

机构持仓方面，截止2025年6月30日，华润三九十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股4361.40万股，相比上期增加705.16万股。华泰柏瑞沪深300ETF（510300）位居第四大流 通股东，持股1193.47万股，相比上期增加356.72万股。易方达沪深300医药ETF（512010）位居第五大 流通股东，持股1096.93万股，相比上期增加185.89万股。易方达沪深300ETF（510310）位居第七大流 通股东，持股848.71万股，相比上期增加261.73万股。中欧医疗健康混合A（003095）退出十大流通股 东之列。 华润三九所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：维生素、禽流感药物、医药 电商、抗流感、化妆品等。 截至9月20日，华润三九股东户数10.04万，较上期增加6.25%；人均流通股16561股，较上期减少 5.88%。2025年1月-6月，华润三九实现营业收入148.10亿元，同比增长4.99%；归母净利润18.15亿元， 同比减少24.31%。 分红方面，华润三九A股上市后累计派现100.69亿元。近三年，累计派现49.15亿元。 1 ...

10月9日，吉林敖东盘中上涨2.15%，截至10:58，报20.44元/股，成交2.92亿元，换手率1.23%，总市值 244.44亿元。 资金流向方面，主力资金净流入823.28万元，特大单买入1466.16万元，占比5.02%，卖出1931.71万元， 占比6.62%；大单买入7803.29万元，占比26.73%，卖出6514.46万元，占比22.31%。 吉林敖东今年以来股价涨20.41%，近5个交易日涨7.07%，近20日涨7.07%，近60日涨19.88%。 分红方面，吉林敖东A股上市后累计派现44.30亿元。近三年，累计派现16.47亿元。 机构持仓方面，截止2025年6月30日，吉林敖东十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股1501.38万股，相比上期增加461.49万股。南方中证500ETF（510500）位居第五大流通股 东，持股1424.79万股，相比上期增加191.48万股。汇添富中证中药ETF（560080）位居第十大流通股 东，持股440.92万股，相比上期减少48.30万股。 责任编辑：小浪快报 资料显示，吉林敖东药业集团股份有限公司位于吉林省敦化市敖东大街 ...

10月9日，康希诺盘中下跌2.02%，截至10:04，报77.91元/股，成交5024.50万元，换手率0.56%，总市值 192.79亿元。 资金流向方面，主力资金净流入293.71万元，特大单买入101.10万元，占比2.01%，卖出0.00元，占比 0.00%；大单买入1010.06万元，占比20.10%，卖出817.45万元，占比16.27%。 截至6月30日，康希诺股东户数1.75万，较上期减少1.92%；人均流通股0股，较上期增加0.00%。2025年 1月-6月，康希诺实现营业收入3.82亿元，同比增长26.00%；归母净利润-1348.54万元，同比增长 94.02%。 分红方面，康希诺A股上市后累计派现1.98亿元。近三年，累计派现0.00元。 责任编辑：小浪快报 康希诺今年以来股价涨27.62%，近5个交易日跌1.38%，近20日跌7.06%，近60日涨30.07%。 资料显示，康希诺生物股份公司位于天津经济技术开发区西区南大街185号西区生物医药园，成立日期 2009年1月13日，上市日期2020年8月13日，公司主营业务涉及研发、生产和商业化符合中国及国际标准 的创新型疫苗企业。主营业 ...

Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.12% on September 25, with a current price of 6.46 CNY per share and a market capitalization of 3.707 billion CNY [1] Company Overview - TaiLong Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, is located in Zhengzhou, Henan Province. The company operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The revenue composition of TaiLong Pharmaceutical includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of June 30, 2025, the number of shareholders is 40,900, a decrease of 11.14%, with an average of 14,037 circulating shares per person, an increase of 12.53% [2] Financial Performance - For the first half of 2025, TaiLong Pharmaceutical reported a revenue of 762 million CNY, a year-on-year decrease of 17.77%, and a net profit attributable to shareholders of 19.35 million CNY, down 27.32% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.53 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the seventh largest circulating shareholder is Guangfa Pension Index A, holding 3.236 million shares as a new shareholder, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF has exited the top ten circulating shareholders [3]

Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. The company was listed on November 16, 2017. Its main business involves the research, production, and sales of proprietary drugs, as well as the sales of agency drugs [1][2]. Financial Performance - As of August 31, Yipinhong reported a revenue of 584 million yuan for the first half of 2025, a year-on-year decrease of 36.02%. The net profit attributable to shareholders was -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has cumulatively distributed 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]. Stock Performance - On September 25, Yipinhong's stock price decreased by 2.00%, trading at 58.30 yuan per share, with a total market capitalization of 26.334 billion yuan. The stock has increased by 241.74% year-to-date but has seen a decline of 4.06% in the last five trading days and 11.84% in the last 20 days [1]. - The stock has appeared on the "龙虎榜" (a stock trading list) five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1]. Shareholder Information - As of August 31, the number of shareholders for Yipinhong was 21,400, an increase of 0.49% from the previous period. The average circulating shares per person decreased by 0.49% to 19,553 shares [2]. - As of June 30, 2025, the eighth largest circulating shareholder is E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares as a new shareholder, while Hong Kong Central Clearing Limited has exited the top ten circulating shareholders [3]. Industry Classification - Yipinhong belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, with concepts including anti-influenza, pharmaceutical e-commerce, hepatitis treatment, monkeypox concept, and traditional Chinese medicine [2].

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 252.81%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its listing date on November 16, 2017 [1]. - The company's main business involves the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The revenue composition is as follows: Children's medicine 61.12%, Chronic disease medicine 22.71%, Others 16.17% [1]. Financial Performance - For the first half of 2025, Yipinhong reported operating revenue of 584 million yuan, a year-on-year decrease of 36.02%, and a net profit attributable to shareholders of -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3]. Shareholder Information - As of August 31, the number of Yipinhong's shareholders was 21,400, an increase of 0.49% from the previous period, with an average of 19,553 circulating shares per person, a decrease of 0.49% [2]. - As of June 30, 2025, Yipinhong's top ten circulating shareholders included E Fund Medical Healthcare Industry Mixed A as the eighth largest shareholder, holding 4.3661 million shares, while Hong Kong Central Clearing Limited exited the top ten list [3]. Market Activity - On September 24, Yipinhong's stock price rose by 2.02% to 60.19 yuan per share, with a trading volume of 218 million yuan and a turnover rate of 0.88%, resulting in a total market capitalization of 27.187 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.5761 million yuan [1].

Company Overview - Guilin Sanjin Pharmaceutical Co., Ltd. is located in the Lingui District of Guilin City, Guangxi Zhuang Autonomous Region, established on February 23, 1994, and listed on July 10, 2009 [2] - The company specializes in the research, production, and sales of traditional Chinese medicine products, including throat and oral medications, anti-urinary tract infection drugs, and cardiovascular drugs, along with other natural medicines and biological preparations [2] - The main business revenue composition is as follows: Industrial 97.26%, Commodity circulation 2.37%, Other 0.38% [2] Stock Performance - As of September 23, the stock price of Guilin Sanjin fell by 2.11%, trading at 14.35 CNY per share, with a total market capitalization of 8.432 billion CNY [1] - Year-to-date, the stock price has decreased by 2.65%, with a 4.01% drop over the last five trading days and a 7.66% decline over the last 20 days [2] - The stock has appeared on the "Dragon and Tiger List" once this year, with the last appearance on January 7, where it recorded a net buy of -177.741 million CNY [2] Financial Performance - For the first half of 2025, Guilin Sanjin reported a revenue of 999.8 million CNY, a year-on-year decrease of 6.56%, and a net profit attributable to shareholders of 287 million CNY, down 4.70% year-on-year [3] - The company has distributed a total of 4.592 billion CNY in dividends since its A-share listing, with 1.175 billion CNY distributed over the last three years [4] Shareholder Information - As of September 10, the number of shareholders for Guilin Sanjin was 21,800, a decrease of 0.78% from the previous period, with an average of 25,628 circulating shares per shareholder, an increase of 0.78% [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 6.3037 million shares, an increase of 1.8371 million shares from the previous period [4] Market Position - Guilin Sanjin is classified under the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [2] - The company is associated with several concept sectors, including anti-influenza, traditional Chinese medicine, small-cap stocks, innovative drugs, and margin financing [2]

Company Overview - Zhenbaodao Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on October 28, 1996, and listed on April 24, 2015. The company focuses on the research, production, and sales of high-end traditional Chinese medicine formulations, with a diverse range of dosage forms and products [2]. Financial Performance - For the first half of 2025, Zhenbaodao reported operating revenue of 714 million yuan, a year-on-year decrease of 57.05%. The net profit attributable to the parent company was -78.29 million yuan, reflecting a year-on-year decline of 119.90% [2]. - Since its A-share listing, Zhenbaodao has distributed a total of 1.302 billion yuan in dividends, with 356 million yuan distributed over the past three years [3]. Stock Performance - As of September 23, Zhenbaodao's stock price decreased by 2.09%, trading at 11.27 yuan per share, with a total market capitalization of 10.605 billion yuan. The stock has seen a decline of 1.57% year-to-date, 8.74% over the last five trading days, 11.05% over the last 20 days, and 3.18% over the last 60 days [1][2]. - The trading volume on September 23 was 17.7324 million yuan, with a turnover rate of 0.17%. The net inflow of main funds was 1.9645 million yuan, with significant buying activity from large orders [1]. Business Segmentation - The main business revenue composition includes: 84.82% from the sale of proprietary Chinese medicines, 7.13% from purchased medicinal materials, 5.11% from purchased pharmaceuticals, 2.51% from other sources, 0.35% from rental income, and 0.07% from interest income [2]. - Zhenbaodao is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine [2]. Shareholder Information - As of July 18, the number of shareholders for Zhenbaodao was 21,500, an increase of 2.34% from the previous period. The average circulating shares per person decreased by 2.29% to 43,744 shares [2].

Core Viewpoint - The stock of Zhendong Pharmaceutical has experienced fluctuations, with a year-to-date increase of 67.82%, but recent declines in the short term raise concerns about its performance [1][2]. Group 1: Stock Performance - On September 23, Zhendong Pharmaceutical's stock fell by 2.03%, trading at 7.25 CNY per share, with a total market capitalization of 7.289 billion CNY [1]. - The stock has seen a net outflow of 6.7912 million CNY in principal funds, with significant selling pressure in the last trading session [1]. - Year-to-date, the stock has increased by 67.82%, but it has declined by 3.85% over the last five trading days and 23.28% over the last 20 days [1]. Group 2: Company Overview - Zhendong Pharmaceutical, established on November 15, 1995, and listed on January 7, 2011, is located in Changzhi, Shanxi Province [2]. - The company specializes in the research, production, and sales of generic and innovative drugs across various therapeutic areas, including oncology and urology [2]. - The revenue composition includes 54.82% from traditional Chinese medicine, 43.10% from chemical drugs, and 1.98% from other sources [2]. Group 3: Financial Performance - For the first half of 2025, Zhendong Pharmaceutical reported a revenue of 1.457 billion CNY, a year-on-year decrease of 3.30%, and a net profit attributable to shareholders of 7.9313 million CNY, down 74.13% year-on-year [2]. - The company has distributed a total of 3.372 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. - As of June 30, 2025, the number of shareholders decreased by 5.04% to 46,100, while the average circulating shares per person increased by 5.31% to 21,777 shares [2].